Skip to main content

Month: July 2025

ST. JAMES GOLD CORP. (TSX-V: LORD) ANNOUNCES REINSTATMENT OF TRADING, DEBT RESOLUTION, AND EXPIRED INVESTOR RELATIONS CONTRACT

Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company” or “St. James”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) announced today that its common shares will be reinstated for trading on the TSX Venture Exchange (the “Exchange”) on or about July 29, 2025 as the TSX Venture Exchange has completed its review. The Company’s financial statements for the period ended March 31, 2025 reflected a working capital deficiency $1,905,769. In order to resolve the deficiency and comply with the Exchange listing requirements, the Company has taken the following steps:The Company has entered into agreements with its largest short-term creditors to issue unsecured notes with a maturity 18 month after issuance to satisfy their indebtedness. A total of $1,580,052.49 of short-term debt is expected to be resolved...

Continue reading

Federal Home Loan Bank of Des Moines Announces Second Quarter 2025 Financial Results, Declares Dividend

DES MOINES, Iowa, July 25, 2025 (GLOBE NEWSWIRE) — Second Quarter 2025 HighlightsNet income of $194 million Affordable Housing Program (AHP) assessments of $21 million Voluntary community and housing contributions of $43 million Advances totaled $114.8 billion Mortgage loans held for portfolio, net totaled $13.2 billion Letters of credit totaled $17.7 billion Retained earnings totaled $3.6 billionDividend The Board of Directors approved a second quarter 2025 dividend to be paid at an annualized rate of 9.75% on average activity-based stock and 6.00% on average membership stock, unchanged from the prior quarter. The Federal Home Loan Bank of Des Moines (the Bank) expects to make dividend payments totaling $145 million on August 12, 2025. Liquidity Mission The Bank provides liquidity to its members to support the housing, business,...

Continue reading

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

Continue reading

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) —  Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

Continue reading

LOBO EV Technologies Ltd. Issues Statement Regarding Recent Market Activity

WUXI, China, July 25, 2025 (GLOBE NEWSWIRE) — LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), a developer and manufacturer in electric mobility and intelligent systems, today issued a statement regarding recent trading activity in its common stock. The Company has observed an increase in trading volume and a corresponding decline in its share price over the past several days. While LOBO does not generally comment on market activity or fluctuations in its stock price, the Company confirms that there have been no material changes to its business operations or strategic direction that would warrant such activity. The Company continues to operate in the ordinary course of business. Current initiatives, including product development and strategic engagements, are ongoing, and management is not aware of any undisclosed...

Continue reading

Lassonde Industries Inc. Will Hold a Conference Call to Discuss Its Second Quarter 2025 Financial Results

ROUGEMONT, Quebec, July 25, 2025 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) is pleased to announce that it will host a conference call to discuss its financial results for the second quarter of 2025 on Friday, August 8, 2025. Mr.  Vince Timpano, Chief Executive Officer, and Mr. Eric Gemme, Chief Financial Officer, will host the call.OPEN TO:  Investors, analysts, and all interested parties   DATE: Friday, August 8, 2025   TIME: 8:30 a.m. ET   CALL: 647-846-8280 (for overseas participants)1-833-752-3549 (for other North American participants)   A live audio broadcast of the conference call will be available on the Corporation’s website, on the Investors page or here: https://www.gowebcasting.com/14099. The replay of the webcast will...

Continue reading

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle. This initiative marks a bold step toward positioning the Company at the forefront of capital innovation, as it evaluates options to diversify its long-term treasury strategy. The prospective subsidiary—which has not yet been formed and remains under active consideration—would operate independently...

Continue reading

Yoshiharu Global Co. Announces Strategic Transition to Vestand Inc.

BUENA PARK, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Yoshiharu Global Co. (NASDAQ: YOSH) (the “Company”), today announced that it plans to change its corporate name to Vestand Inc., and has secured $6.0 million in strategic funding from U.S. and Korean investors to support this transition into a PropTech company. The Company also announced a substantial enhancement of its internal control policy, reinforcing its commitment to transparency and long-term growth as a publicly listed entity. Corporate Name Change and Business TransitionOn July 10, 2025, the Company’s Board of Directors approved the name change to Vestand Inc., marking its transformation from a traditional restaurant operator into a diversified brand that also includes real estate development and digital asset ventures. The Company has initiated the renaming...

Continue reading

VERSES® Featured in IEEE Spectrum

Spatial Web standards and use cases featured in IEEE flagship publication VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, has been featured in IEEE Spectrum, the flagship publication of the IEEE, the world’s largest professional organization devoted to engineering and the applied sciences. The article, co-authored by VERSES CEO Gabriel René, addresses questions such as: Why does the Spatial Web matter? How, exactly, can it make the world better? These are answered with five example use cases for the Spatial Web:Energy saving agents at home; Coordinated mobility standards for autonomous vehicles; Drones using HSML to read a dynamic map; Digital...

Continue reading

Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds

Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or prepay the exercise price) certain existing warrants to purchase up to 2,023,228 shares of common stock (the “Existing Warrants”) at a reduced exercise price of $1.90 per share. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction. The resale of the shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.